Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRJ1 3024

X
Drug Profile

PRJ1 3024

Alternative Names: PRJ1-3024

Latest Information Update: 06 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MingMed Biotechnology
  • Developer MingMed Biotechnology; Xi'An Yufan Biotechnology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 06 Jul 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (PO) (NCT05315167) (MingMed Biotechnology pipeline, July 2022)
  • 06 Jul 2022 Regulatory body approves CTA in Solid tumours in China, prior to July 2022 (MingMed Biotechnology pipeline, July 2022)
  • 11 Apr 2022 Xi'An Yufan Biotechnology (Zhuhai Yufan Biotechnologies) plan to initiate a phase I/II trial in Solid tumors (Late-stage disease, Metastatic disease) in China (PO) by April 2022 (NCT05315167)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top